Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Katherine M. Bever

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5230-4661; OpenAlex author ID A5084756293. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 2, last author 0)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper, 1 trial · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper, 1 trial · 2026: 6 papers

Papers 15

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  3. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  4. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  5. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Co-author DOI 10.1158/2326-6066.cir-25-0545↗
  6. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Co-author DOI 10.1158/2326-6066.cir-25-1126↗
  7. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrop… Co-author DOI 10.1080/2162402x.2025.2543614↗
  8. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.179292↗
  9. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  10. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
  11. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  12. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-20-1025↗
  13. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  14. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Co-author DOI 10.1111/hpb.12334↗
  15. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. First author DOI 10.3791/4059↗

Trials 2

  1. NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer Principal investigator NCT06941857↗
  2. Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer Principal investigator NCT05014776↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 13 shared papers, 2013–2026 · strength 1.96
  2. Dung Thi Le · 10 shared papers, 2020–2026 · strength 1.61
  3. Won Jin Ho · 8 shared papers, 2020–2026 · strength 1.46
  4. Daniel A. Laheru · 10 shared papers, 2015–2026 · strength 1.45
  5. Hao Wang · 7 shared papers, 2022–2026 · strength 1.34
  6. Elana Judith Fertig · 6 shared papers, 2020–2026 · strength 1.07
  7. Robert A. Anders · 8 shared papers, 2013–2026 · strength 1.05
  8. Nilofer Saba Azad · 5 shared papers, 2021–2026 · strength 0.83
  9. Jae Woo Lee · 4 shared papers, 2026 · strength 0.83
  10. Amanda L. Huff · 4 shared papers, 2026 · strength 0.81
  11. Luciane Tsukamoto Kagohara · 4 shared papers, 2024–2026 · strength 0.74
  12. Janelle Marie Montagne · 3 shared papers, 2026 · strength 0.61
  13. Dimitrios N. Sidiropoulos · 3 shared papers, 2024–2026 · strength 0.58
  14. Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
  15. Marina Baretti · 3 shared papers, 2026 · strength 0.58
  16. Mark M. Yarchoan · 3 shared papers, 2026 · strength 0.58
  17. Neeha Zaidi · 3 shared papers, 2026 · strength 0.58
  18. Nicole Groß · 3 shared papers, 2024–2026 · strength 0.56
  19. Ana De Jesus‐Acosta · 5 shared papers, 2015–2023 · strength 0.53
  20. Matthew Z. Guo · 2 shared papers, 2026 · strength 0.46
  21. Eric Scott Christenson · 2 shared papers, 2022–2026 · strength 0.40
  22. Jacob T. Mitchell · 2 shared papers, 2024–2026 · strength 0.39
  23. Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
  24. Lei Zheng · 4 shared papers, 2013–2021 · strength 0.26
  25. William Reece Burns · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.